Nanomedical Research

Topic Information

Dear Colleagues,

Nanomedicine is a rapidly evolving research area with a strong interdisciplinary character, requiring the interaction of scientists from different disciplines, such as chemistry, engineering, physics, biology, biotechnology, medicine, and pharmacology. Nanoconstructs intended for biomedical purposes cover a wide variety of potential applications: systems for the targeted delivery of therapeutic compounds; agents for bioimaging; biosensors; biomarkers; robots at the molecular scale; components for membranes, coatings, films, or scaffolds; etc.

This Topic aims to collect articles dealing with any aspect of nanoscience and nanotechnology applied to biology and medicine, from the design, synthesis, and characterization of novel nanomaterials and nanoconstructs to the evaluation of their effects in applications within the biomedical field. Particular attention is devoted to the development of innovative methodological approaches and technological tools.

The Topic is open to basic and applied science as well as to preclinical studies; submissions of both original research and review articles from researchers, clinicians, and the industry are all welcome.

Prof. Manuela Malatesta
Prof. Dr. Federico Boschi
Dr. Flavia Carton
Topic Editors

Keywords

Participating Journals

Journal Name	Impact Factor	CiteScore	Launched Year	First Decision (median)	APC
Biomedicines biomedicines	4.7	3.7	2013	15.4 Days	CHF 2600
Current Issues in Molecular Biology cimb	3.1	2.4	1999	13.5 Days	CHF 2200
International Journal of Molecular Sciences ijms	5.6	7.8	2000	16.3 Days	CHF 2900
Nanomaterials nanomaterials	5.3	7.4	2010	13.6 Days	CHF 2900
Pharmaceutics pharmaceutics	5.4	6.9	2009	14.2 Days	CHF 2900

MDPI Topics is cooperating with Preprints.org and has built a direct connection between MDPI journals and Preprints.org. Authors are encouraged to enjoy the benefits by posting a preprint at Preprints.org prior to publication:

1. Immediately share your ideas ahead of publication and establish your research priority;
2. Protect your idea from being stolen with this time-stamped preprint article;
3. Enhance the exposure and impact of your research;
4. Receive feedback from your peers in advance;
5. Have it indexed in Web of Science (Preprint Citation Index), Google Scholar, Crossref, SHARE, PrePubMed, Scilit and Europe PMC.

Published Papers (3 papers)

Order results

Content type Publication Date

Result details

Normal Extended Compact

Journals

All Biomedicines CIMB IJMS Nanomaterials Pharmaceutics

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

Error

Oops... you haven't selected anything for export.

Ok

clear

attachment

Supplementary material:
Supplementary File 1 (ZIP, 4368 KiB)

19 pages, 4624 KiB  

Open AccessEditor’s ChoiceArticle

Novel Golden Lipid Nanoparticles with Small Interference Ribonucleic Acid for Substrate Reduction Therapy in Fabry Disease

by Marina Beraza-Millor, Julen Rodríguez-Castejón, Jonatan Miranda, Ana del Pozo-Rodríguez, Alicia Rodríguez-Gascón and María Ángeles Solinís

Pharmaceutics 2023, 15(7), 1936; https://doi.org/10.3390/pharmaceutics15071936 - 12 Jul 2023

Cited by 2 | Viewed by 1410

Abstract

Substrate reduction therapy (SRT) has been proposed as a new gene therapy for Fabry disease (FD) to prevent the formation of globotriaosylceramide (Gb3). Nanomedicines containing different siRNA targeted to Gb3 synthase (Gb3S) were designed. Formulation factors, such as the composition, solid lipid nanoparticles [...] Read more.

Substrate reduction therapy (SRT) has been proposed as a new gene therapy for Fabry disease (FD) to prevent the formation of globotriaosylceramide (Gb3). Nanomedicines containing different siRNA targeted to Gb3 synthase (Gb3S) were designed. Formulation factors, such as the composition, solid lipid nanoparticles (SLNs) preparation method and the incorporation of different ligands, such as gold nanoparticles (GNs), protamine (P) and polysaccharides, were evaluated. The new siRNA–golden LNPs were efficiently internalized in an FD cell model (IMFE-1), with GNs detected in the cytoplasm and in the nucleus. Silencing efficacy (measured by RT-qPCR) depended on the final composition and method of preparation, with silencing rates up to 90% (expressed as the reduction in Gb3S-mRNA). GNs conferred a higher system efficacy and stability without compromising cell viability and hemocompatibility. Immunocytochemistry assays confirmed Gb3S silencing for at least 15 days with the most effective formulations. Overall, these results highlight the potential of the new siRNA–golden LNP system as a promising nanomedicine to address FD by specific SRT. Full article

(This article belongs to the Topic Nanomedical Research)

►▼ Show Figures

Graphical abstract

attachment

Supplementary material:
Supplementary File 1 (ZIP, 7061 KiB)

26 pages, 4983 KiB  

Open AccessArticle

Immunosuppressive Polymeric Nanoparticles Targeting Dendritic Cells Alleviate Lupus Disease in Fcgr2b^-/- Mice by Mediating Antigen-Specific Immune Tolerance

by Phuriwat Khiewkamrop, Chamraj Kaewraemruaen, Chonnavee Manipuntee, Chalathan Saengruengrit, Numpon Insin, Asada Leelahavanichkul, Warerat Kaewduangduen, Opor Sonpoung, Kasirapat Ariya-anandech, Nattiya Hirankarn and Patcharee Ritprajak

Int. J. Mol. Sci. 2023, 24(9), 8313; https://doi.org/10.3390/ijms24098313 - 05 May 2023

Cited by 2 | Viewed by 1708

Abstract

Dendritic cells (DCs) are the most potent antigen-presenting cells that have multifaceted functions in the control of immune activation and tolerance. Hyperresponsiveness and altered tolerogenicity of DCs contribute to the development and pathogenesis of system lupus erythematosus (SLE); therefore, DC-targeted therapies aimed at [...] Read more.

Dendritic cells (DCs) are the most potent antigen-presenting cells that have multifaceted functions in the control of immune activation and tolerance. Hyperresponsiveness and altered tolerogenicity of DCs contribute to the development and pathogenesis of system lupus erythematosus (SLE); therefore, DC-targeted therapies aimed at inducing specific immune tolerance have become of great importance for the treatment of SLE. This study developed a new nanoparticle (NP) containing a biodegradable PDMAEMA-PLGA copolymer for target-oriented delivery to DCs in situ. PDMAEMA-PLGA NPs provided sustained drug release and exhibited immunosuppressive activity in FLT3L and GM-CSF-derived bone marrow in conventional DCs (BM-cDCs). PDMAEMA-PLGA NPs improved dexamethasone capability to convert wild-type and Fcgr2b^-/- BM-cDCs from an immunogenic to tolerogenic state, and BM-cDCs treated with dexamethasone-incorporated PDMAEMA-PLGA NPs (Dex-NPs) efficiently mediated regulatory T cell (Treg) expansion in vitro. Dex-NP therapy potentially alleviated lupus disease in Fcgr2b^-/- mice by mediating Foxp3⁺ Treg expansion in an antigen-specific manner. Our findings substantiate the superior efficacy of DC-targeted therapy using the PDMAEMA-PLGA NP delivery system and provide further support for clinical development as a potential therapy for SLE. Furthermore, PDMAEMA-PLGA NP may be a versatile platform for DC-targeted therapy to induce antigen-specific immune tolerance to unwanted immune responses that occur in autoimmune disease, allergy, and transplant rejection. Full article

(This article belongs to the Topic Nanomedical Research)

►▼ Show Figures

Figure 1

16 pages, 1728 KiB  

Open AccessReview

HIV Latency and Nanomedicine Strategies for Anti-HIV Treatment and Eradication

by Mickensone Andre, Madhavan Nair and Andrea D. Raymond

Biomedicines 2023, 11(2), 617; https://doi.org/10.3390/biomedicines11020617 - 18 Feb 2023

Cited by 5 | Viewed by 2340

Abstract

Antiretrovirals (ARVs) reduce Human Immunodeficiency Virus (HIV) loads to undetectable levels in infected patients. However, HIV can persist throughout the body in cellular reservoirs partly due to the inability of some ARVs to cross anatomical barriers and the capacity of HIV-1 to establish [...] Read more.

Antiretrovirals (ARVs) reduce Human Immunodeficiency Virus (HIV) loads to undetectable levels in infected patients. However, HIV can persist throughout the body in cellular reservoirs partly due to the inability of some ARVs to cross anatomical barriers and the capacity of HIV-1 to establish latent infection in resting CD4⁺ T cells and monocytes/macrophages. A cure for HIV is not likely unless latency is addressed and delivery of ARVs to cellular reservoir sites is improved. Nanomedicine has been used in ARV formulations to improve delivery and efficacy. More specifically, researchers are exploring the benefit of using nanoparticles to improve ARVs and nanomedicine in HIV eradication strategies such as shock and kill, block and lock, and others. This review will focus on mechanisms of HIV-1 latency and nanomedicine-based approaches to treat HIV. Full article

(This article belongs to the Topic Nanomedical Research)

►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less

Select all

Export citation of selected articles as:

Plain Text BibTeX BibTeX (without abstracts) Endnote Endnote (without abstracts) Tab-delimited RIS

 

Error

Oops... you haven't selected anything for export.

Ok

clear

Displaying articles 1-3